Pro Medicus (ASX:PME) - CEO Dr Sam Hupert
CEO Dr Sam Hupert
Source: Pro Medicus
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Pro Medicus (PME)’s wholly owned subsidiary has signed a $40 million contract with Novant Health
  • Visage Imaging penned a seven-year contract, which will see the company’s Visage 7 Enterprise Imaging Platform and Visage 7 Workflow module implemented throughout Novant Health
  • Planning for the rollout is set to start immediately, with launch dates targeted for the second half of the financial year, deployed on the Microsoft Azure cloud
  • Pro Medicus is down 1.1 per cent, trading at $54.01 at 12:20 pm AEST

Pro Medicus (PME)’s wholly owned subsidiary has signed a $40 million contract with Novant Health.

Visage Imaging penned the seven-year contract which will see the company’s Visage 7 Enterprise Imaging Platform and Visage 7 Workflow module implemented throughout Novant Health, providing a unified diagnostic imaging platform across the network.  

Planning ahead of the rollout is set to start immediately, with launch dates targeted for the second half of the financial year.

Pro Medicus CEO Sam Hupert explained the implementation would be fully deployed on the Microsoft Azure cloud.

“Novant Health is our seventh major North American contract in less than 18 months and our equal largest deal to date, underpinning the strong momentum we continue to build in the market,” Dr Hupert said.

Novant Health also joins an increasing number of clients to opt for a fully cloud-based solution.

“Our pipeline remains strong. Deals like this confirm our view that Visage 7, with its proven cloud native technology and modular design, provides us with a significant strategic advantage that enables us to address opportunities across a growing segment of the market both in North America and other regions,” Dr Hupert said.

Pro Medicus was down 1.1 per cent, trading at $54.01 at 12:20 pm AEST.

PME by the numbers
More From The Market Herald
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…

" Antisense Therapeutics (ASX:ANP) dosing of muscular dystrophy drug on hold

Antisense Therapeutics (ASX:ANP) applies for partial clinical hold that limits dosing of its drug for muscular…
Antisense Therapeutics (ASX:ANP) - MD and CEO, Mark Diamond

" Antisense Therapeutics (ASX:ANP) to present new data

Antisense Therapeutics (ASX:ANP) announces its new proteomics data will be presented in a virtual congress.